Compare Abbott Laboratories (ABT) vs Lithium Americas Corp (LAC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Lithium Americas Corp — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Lithium Americas Corp trades at $3.54 (market cap $1.27B). The key difference: Abbott Laboratories is far larger — about 131.4× Lithium Americas Corp's market cap, and Abbott Laboratories pays a 2.63% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals.
| ABT | LAC | |
|---|---|---|
Market Cap | $166.94B | $1.27B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $10.05 |
52-Week Low | $82.57 | $2.55 |
Enterprise Value | $193.69B | $1.39B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Lithium Americas (LAC) trades at $3.82, up 1.6% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -11.35% and net income of -$122.09M for 2025, though cash flow from financing surged to $1.14B. Construction milestones at Thacker Pass dominate recent news, with analyst consensus leaning toward Hold (53.33%) versus Buy (46.67%) and a $6.25 price target suggesting 64% upside potential.
Outlook remains speculative with high execution risk on Thacker Pass development requiring $1.3-1.6B in 2026 capex. Government support and lithium demand underpin long-term opportunity, but near-term dilution risk from ATM share issuances and negative cash flow from operations (-$61.22M) pressure equity valuation. Investors face binary outcome: project success drives multi-bag returns, while delays or cost overruns could erode shareholder value further.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
